br Competing financial interests declaration br The author h
Competing financial interests declaration
The author has previously done consulting for EPRI, not related to this work.
No external funding was obtained for this study.
Appendix A. Supporting information
Ahlbom, A., Feychting, M., Green, A., Kheifets, L., Savitz, D.A., Swerdlow, A.J., ICNIRP (International Commission for Non-Ionizing Radiation Protection) Standing Committee on Epidemiology, 2009. Epidemiologic evidence on mobile phones and tumor risk: a review. Epidemiology 20 (5), 639–652.
Akhavan-Sigari, R., Mazloum Farsi BAF, M., Ariabod, V., Rohde, V., Rahighi, S., 2014. Connection between cell phone use, p53 gene Pertussis Toxin in different zones of glio-blastoma multiforme and survival prognoses. Rare Tumors 6 (5350). Baan, R., Grosse, Y., Lauby-Secretan, B., EL Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N., Islami, F., Galichet, L., Straif, K., WHO International Agency for Research on Cancer Monograph Working Group, 2011. arcinogenicity of radio-frequency electromagnetic fields. Lancet Oncol. 12 (7), 624–626.
Broderson, K.H., Hauser, A., 2017. CausalImpact: Inferring Causal Effects using Bayesian Structural Time-Series Models 〈https://CRAN.R-project.org/package= CausalImpact〉 (Accessed 11 September 2018).
Health And Social Care Information Centre (Hscic), 2015. Health Survey for England,
F. de Vocht
2014: Trend tables. Available from:. 〈https://www.gov.uk/government/statistics/ health-survey-for-england-trend-tables-2014〉 (Accessed 11 September 2018). Hardell, L., Carlberg, M., Hansson Mild, K., 2013. Use of mobile phones and cordless phones is associated with increased risk for glioma and acoustic neuroma. Pathophysiology 20, 85–110.
Interphone Study Group, 2010. Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study. Int. J. Epidemiol. 39, 675–694. Interphone Study Group, 2011. Acoustic neuroma risk in relation to mobile telephone use: results of the interphone international case-control study. Cancer Epidemiol. 35, 453–464. ITU, 2016. Time Series by Country (until 2014). [Online]. Available from:. 〈http://www. itu.int/en/ITU-D/Statistics/Pages/stat/default.aspx〉 (Accessed 4 October 2016).
NTP, 2018a. NTP technical report on the toxicology and carcinogenesis studies in Hsd:sprague dawley SD rats exposed to whole-body radio frequency radiation at a frequency (900 MHz) and modulations (GSM AND CDMA) used by cell phones National Toxicology Program. Available from: 〈https://ntp.niehs.nih.gov/ntp/about_ ntp/trpanel/2018/march/tr595peerdraft.pdf〉 (Accessed 11 September 2018). NTP, 2018b. Toxicology and carcinogenesisstudies in B6C3F1/N mice exposed to whole-body radio frequency radiation at a frequency (1,900 MHz) and modulations (GSM AND CDMA) used by cell phones. NIH. Available from: 〈https://ntp.niehs.nih.gov/ Environmental Research 168 (2019) 329–335
Contents lists available at ScienceDirect
Analysis of a National Programme for Selective Internal Radiation Therapy for Colorectal Cancer Liver Metastases
z Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, London, UK x Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge, UK Nottingham University Hospitals NHS Trust, Nottingham, UK jj Leeds Teaching Hospitals NHS Trust, St James’s Hospital, Leeds, UK ** Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK yy The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne, UK zz NHS England, Institute of Oncology, St James’s University Hospital, Leeds, UK
xx The Christie NHS Foundation Trust, Withington, Manchester, UK NIHR University College London Hospitals Biomedical Research Centre, UCL Cancer Institute, University College London, London, UK
Aims: Patients with chemotherapy-refractory colorectal cancer liver metastases have limited therapeutic options. Selective internal radiation therapy (SIRT) delivers yttrium 90 microspheres as a minimally invasive procedure. This prospective, single-arm, observational, service-evaluation study was part of National Health Service England Commissioning through Evaluation.
Methods: Patients eligible for treatment had histologically confirmed carcinoma with liver-only/liver-dominant metastases with clinical progression during or following oxaliplatin-based and irinotecan-based chemotherapy. All patients received SIRT plus standard of care. The primary outcome was overall survival; secondary outcomes included safety, progression-free survival (PFS) and liver-specific PFS (LPFS).